These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22487716)

  • 41. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke.
    Rawlins SM
    Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816
    [No Abstract]   [Full Text] [Related]  

  • 42. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

  • 43. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. US seeking more transparency from pharma.
    Collier R
    CMAJ; 2016 Apr; 188(7):E115. PubMed ID: 26976964
    [No Abstract]   [Full Text] [Related]  

  • 45. The marketing of pharmaceutical agents: friend or foe?
    Jurd S
    Australas Psychiatry; 2010 Apr; 18(2):97-100. PubMed ID: 20307151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Development costs, regulation and audit in the German SHI Drug Sector].
    Kamp F; Walter P; Bücheler R
    Gesundheitswesen; 2014 Jan; 76(1):7-18. PubMed ID: 24446140
    [No Abstract]   [Full Text] [Related]  

  • 47. European scheme to develop drugs for diseases with no treatment launched.
    Hawkes N
    BMJ; 2016 Mar; 352():i1385. PubMed ID: 26957004
    [No Abstract]   [Full Text] [Related]  

  • 48. Redesigner drugs.
    Dove A
    Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vendor competition, generic drugs spur drop in pharmaceutical prices.
    Seigner CA
    Mod Healthc; 1985 Oct; 15(21):56, 60-2. PubMed ID: 10317662
    [No Abstract]   [Full Text] [Related]  

  • 50. [Germany's Novartis Chief proposes "More competition through decentralized contracts"].
    Kosche D; Färber L
    MMW Fortschr Med; 2010 Aug; 152(31-33):6-7. PubMed ID: 20828056
    [No Abstract]   [Full Text] [Related]  

  • 51. Drug industry is considering more use of differential pricing, conference hears.
    Sukkar E
    BMJ; 2011 Dec; 343():d8049. PubMed ID: 22155726
    [No Abstract]   [Full Text] [Related]  

  • 52. How NICE may be outflanked.
    Ferner RE; McDowell SE
    BMJ; 2006 May; 332(7552):1268-71. PubMed ID: 16735342
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmaceutical industry financial performance.
    Goodman M
    Nat Rev Drug Discov; 2009 Dec; 8(12):927-8. PubMed ID: 19949398
    [No Abstract]   [Full Text] [Related]  

  • 54. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 56. Putting your best mode forward.
    Tsao YR; Tabtiang RK
    Nat Biotechnol; 2000 Oct; 18(10):1113-4. PubMed ID: 11017054
    [No Abstract]   [Full Text] [Related]  

  • 57. Resurrection men dig through the drug graveyard: ARYx revives problem blockbuster drugs.
    Wolfson W
    Chem Biol; 2005 Nov; 12(11):1155-6. PubMed ID: 16298292
    [No Abstract]   [Full Text] [Related]  

  • 58. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mergers in Japan help firms retain own products.
    Fuyuno I
    Nat Rev Drug Discov; 2005 May; 4(5):358. PubMed ID: 15902766
    [No Abstract]   [Full Text] [Related]  

  • 60. Medicine and the pharmaceutical industry.
    Baxter P
    Dev Med Child Neurol; 2006 Aug; 48(8):627. PubMed ID: 16836771
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.